2023 Sustainability Report
Lilly unites caring with discovery to create medicines that make life better for people around the world. We strive to set measurable goals to track the progress and performance of our sustainability strategy. Our goals help drive accountability and are grounded in our purpose to create medicines that make life better.
“We set aggressive goals, we’re transparent with our progress, and we hold ourselves accountable. This puts us on a more solid foundation to discover and develop new medicines and serve the patients who need them”, Dave Ricks.
As a medicine company dedicated to improving human health for nearly 150 years, Lilly unites caring and discovery to create medicines that make life better for people around the world. Driven by this purpose, we work to launch innovative breakthroughs for serious diseases, strengthen our communities and serve as good stewards of our natural resources.
This holistic approach to sustainability has always been integral to how we operate. We continue to set aggressive goals, report on our progress and hold ourselves accountable. Sustainability highlights since our last report include:
Advancing toward our 2030 climate goals of being carbon neutral in our own operations and purchasing all our electricity from renewable sources. We purchased 28% of our electricity from renewable sources in 2023 and reduced our greenhouse gas emissions by 26% since 2020, while our business has grown.
Signing a renewable power purchase agreement for a new large-scale wind farm, which will generate approximately 450,000 megawatt-hours per year of renewable energy, representing over 90% of our electrical demand in North America.
Providing $4.3 billion in medicines in 2023 to charitable organizations that offer medicines at no cost to qualifying patients around the world. This included more than $68 million in medicines to humanitarian organizations that support disaster preparedness, disaster relief and humanitarian aid.
Reaching an estimated 18 million people in 2023 as part of our 30x30 goal of improving quality health care for 30 million people living in resource-limited settings annually by 2030.
Making insulin more affordable, reducing the U.S. list price of our most commonly prescribed insulins by 70% and capping out-of-pocket costs at $35 per month1.
As we move forward, sustainability and purpose will remain essential to our efforts to advance human health and make life better for all our stakeholders. Thank you for your interest in our work and support of our progress.
Dave Ricks, CEO
Read more on the website
Tags in this Article:
Related articles
Progress on Alzheimer’s Disease stagnating, warns Alzheimer Disease International CEO...
While stopping the progression of Alzheimer’s disease is not yet possible, hope is on the horizon in the form of new breakthroughs in diagnostics and new treatments. Yet scientific advances alone are not enough; public awareness, clinical practice and healthcare systems across the world must evolve in-step with scientific progress to drive confidence in what can now be achieved and deliver meaningful change for those affected.
Improving Early Detection and Diagnosis of Alzheimer’s disease
Research has undisputably shown that the key to preventing or delaying the cognitive decline associated with Alzheimer’s disease (AD) lies in early and accurate detection and diagnosis. Through this, patients can be provided with the opportunity to receive the right treatment at the right time. Not only can this improve their quality of life, but it has the potential to reduce long-term care costs associated with AD.
Alzheimer’s Policy
At Lilly, we’ve remained committed to taking on Alzheimer’s disease (AD) from every angle for the last three decades. Our vision is that in 10 years, timely detection, accurate diagnosis, appropriate treatment and ultimately prevention will be a reality. We are proud to support Alzheimer Europe’s novel #DementiaNeedsEU campaign, which encourages policy makers to prioritise dementia and take concrete steps to ensure that people affected by the condition are supported to live as well as they can.